Document:

EX-10.4

 Exhibit 10.4 

Portions of this Exhibit have been redacted because they are both (i) not material and (ii) the 

registrant customarily and actually treats such information as private or confidential. Information 

that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. 

AMENDMENT NO 1 TO C5 PLA 
 THIS
AMENDMENT NO 1 to the Product License Agreement dated March 9, 2012, as subsequently supplemented by a Letter Agreement dated November 4, 2015 (the “C5 PLA”), is entered into with effect as of
January 1, 2018 (the “Effective Date”), and made between: 
  

	(1)	 Affibody AB, corp. reg. no 556665-6913, Gunnar Asplunds Allé 24, SE-171 63 Solna (“Affibody”); and 

  

	(2)	 Swedish Orphan Biovitrum AB (publ), corp. reg. no 556038-9321, SE-112 76 Stockholm (“Licensee”). 

 Affibody and Licensee are
collectively referred to as the “Parties”. 
  

	1.	 BACKGROUND INFORMATION 

 

	1.1	 Affibody and Licensee will, together with third parties, participate within a [***] funded research project
named “[***]” (the “[***]”). The parties to the [***] have executed a [***] dated [***] “(“[***]”), and may execute additional agreements within the scope of the [***]. The Main
Agreement and any such agreements are jointly referred to as “[***]”. 

  

	1.2	 Sobi wishes to use a specific Affibody® Ligand in the
[***]. 

  

	1.3	 In view of this, the Parties hereby agree as follows. 

 

	2.	 AMENDMENTS 

  

	2.1	 Notwithstanding the provisions of the C5 PLA, including section 3.6, Licensee may use the Affibody® Ligand included in [***] (as specified in Appendix A) in research project carried out within the scope of the [***], and in connection therewith transfer and make available such Affibody® Ligand to the other parties in the [***]. 

  

	2.2	 Licensee agrees that the C5 PLA, including Licensee’s exclusive licenses and Target exclusivity pursuant
to section 5 of the C5 PLA, does not preclude Affibody from participating in the [***]. In addition, each of Affibody’s and Licensee’s rights under the C5 PLA are subject to any conflicting obligations of Licensee and Affibody, as the case
may be, to provide access rights to intellectual property under the [***] (including “[***]” and “[***]” as defined therein) to the other parties in the [***]. 

 

	2.3	 Notwithstanding clause 2.2 above, as between the Parties, any “[***]”, shares in
“[***]” and “[***]” (each term as defined in the Main Agreement) generated and/or owned by any of Affibody and Licensee under the [***], and relating to the Product Technology (including the Affibody® Ligand(s)) or the Platform Technology jointly referred to as “[***]”), shall be treated as if such [***] and corresponding intellectual property rights had been generated under the
scope of the C5 PLA. This means e.g. that any Improvements 

	 	
to the Affibody® Ligand(s) as such shall be considered as Product Technology, and that any Improvements to the Affibody®  Molecule Technology shall be considered as Platform Technology. Likewise, any patents and patent applications covering [***] shall be treated as Licensed Patents or Product Patents, as and
when applicable, and the term “Valid Claim” under the C5 PLA, and Licensee’s royalty obligations under the C5 PLA shall include also such patents and patent applications. For this purpose, each of Affibody and Licensee agrees to sign,
and cause its employees and consultants to sign, such documents and take such other measures deemed necessary and required by the other Party to secure a transfer of such [***] in accordance with this clause 2.3. 

 

	2.4	 If it is not possible to allocate [***] between Affibody and Licensee as stated in clause 2.3, e.g. due to
legal or contractual restrictions under the [***], then the affected Party shall fulfil any obligations relating to such [***] on behalf of the other Party, which shall acquire such income and rights pursuant thereto that would otherwise have been
due if such transfer actually had occurred, and the Parties shall endeavor to negotiate a substitute arrangement that best reflects the economic intentions of the Parties without being unenforceable, and shall execute all agreements and documents
required in this respect. For the avoidance of doubt, this is not intended to amend section 22.4 of the C5 PLA (Relationship of the Parties). 

  

	2.5	 Each Party agrees to consult with the other Party before granting rights to the other parties in the [***] to
[***] or other intellectual property rights that are covered by the C5 PLA. 

  

	3.	 OTHER 

  

	3.1	 Except as modified hereby, the C5 PLA shall remain in full force and effect between the Parties. Capitalized
terms used in this Amendment No 1 shall have the same meaning as set out in the C5 PLA unless explicitly stated otherwise. 

  

	3.2	 If there is a conflict between the terms of the C5 PLA and this Amendment No 1, this Amendment No 1 shall
control as to the [***]. 

  

	3.3	 For clarity, the provisions on confidentiality (section 13),indemnity, etc. (section 16), and choice of law and
arbitration (section 21) in the C5 PLA shall apply also to this Amendment No 1. 

									
		 	AFFIBODY AB	 		 		 	SWEDISH ORPHAN BIOVITRUM AB (PUBL)
					
		 	 /s/ David Bejker
	 		 		 	 /s/ Carin Dahlquist

		 	 David Bejker, CEO
	 		 		 	 Carin Dahlquist, Associate GC

					
		 		 		 		 	 /s/ Kirsti Gjellan

		 		 		 		 	 Kirsti Gjellan, SVP, Head of Manufacturing OperationsEX-10.5

 Exhibit 10.5 

Portions of this Exhibit have been redacted because they are both (i) not material and (ii)

the registrant customarily and actually treats such information as private or confidential. Information 

that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. 

AMENDMENT NO 2 TO C5 PLA 
 THIS
AMENDMENT NO 2 to the Product License Agreement dated March 9, 2012, as subsequently supplemented by a Letter Agreement dated November 4, 2015 and amended by Amendment No. 1 dated January 1, 2018 (the “C5
PLA”), is entered into with effect as of 22 December 2020, and made between: 
  

	(1)	 Affibody AB, corp. reg. no 556665-6913, Scheeles väg 2,
SE-171 65 Solna, Sweden (“Licensor”); and 

  

	(2)	 IPC Research, LLC, a Delaware company and a wholly-owned subsidiary of Rallybio Holdings, LLC, 234
Church Street, Suite 1020, New Haven, CT 06510, USA (“Licensee”). 

 Affibody and Licensee is each a
“Party” and are collectively referred to as the “Parties”. 
  

	1.	 BACKGROUND INFORMATION 

 

	1.1	 The Parties are parties to the C5 PLA, following an assignment from the original licensee Swedish Orphan
Biovitrum AB (publ) (“Sobi”) to Licensee, under which Sobi assigned and transferred all of Sobi’s rights and obligations under the C5 PLA to Licensee, and Licensee substituted Sobi as a party to the C5 PLA.

  

	1.2	 Licensor and Licensee, respectively, have filed new patent applications claiming inter alia Affibody® Ligand(s) as well as other Target binding Affibody® Molecules in several countries. 

 

	1.3	 Patent applications filed by Licensor include international patent application [***] and [***] and that is
listed in Appendix 1 hereto (collectively the “Affibody Applications”), including, but not limited to Affibody’s [***] (the “Affibody [***] Application”). The Affibody Applications relate to Improvements
to the Affibody® Molecule Technology that were made, conceived or reduced to practice by employees of Sobi prior to the date Licensee substituted for Sobi as described in Section 1.1 of
this Amendment No. 2, and subsequently assigned to Licensor in accordance with Section 11.1 of the C5 PLA, and constitute Licensed Patents. 

  

	1.4	 Patent applications filed by Licensee include international patent application [***] and [***] (collectively
the “Licensee Applications”) including, but not limited to, Licensee’s [***] (the “Licensee [***] Application”). The Licensee Applications relate to Affibody®
Molecules that bind to the Target, including Affibody® Ligands (which include those molecules for which amino acid sequences of the C5 (i.e. Target) binding motif are provided in the Licensee
Applications), and therefore constitute Product Patents, but also relate to other Affibody® Molecules binding to the Target (which thus are not Affibody® Ligands)). 

  
 1 

	1.5	 As contemplated by Sections 2.4 and 3.4 of the C5 PLA, Licensee has notified Licensor that it wishes to have a
license to Improvements to the Affibody® Molecule Technology, and accordingly the Parties have agreed to add the Affibody Applications to the list of Licensed Patents in Appendix B of the C5
PLA as set forth in this Amendment No. 2. 

  

	1.6	 In the light of the fact that the [***] recently rejected the Affibody [***] Application and the Licensee [***]
Application on the basis that the applications had overlapping claims, the Parties have also executed this Amendment No. 2 to regulate their agreement in relation to the Affibody [***] Application and the Licensee [***] Application, and to set
forth their intention to work together in good faith to address any similar issues that have arisen or may arise with respect to any other Affibody Applications or Licensee Applications in any country. 

 

	1.7	 The Parties have further agreed to re-establish the Information Sharing
Committee (“ISC”) as set forth in this Amendment No. 2. 

  

	2.	 AMENDMENTS 

  

	2.1	 Limitation of Affibody [***] Application. Subject to the terms and conditions of this Amendment
No. 2, and the additional licenses granted to Licensor herein, Licensor agrees to amend, and has amended, the claims of the Affibody [***] Application to remove Affibody® Molecules
binding to the Target from the claim scope. To the extent that, notwithstanding these amendments, the claim scope of the Affibody [***] Applications still includes any Affibody® Molecules
binding to the Target, Affibody hereby grants to Licensee a license under such Affibody [***] Application that is exclusive with respect to the use of the Affibody Ligands within the Field, to mirror what is set out in Section 3.1b) of the C5
PLA. 

  

	2.2	 Additional Exclusive License Relating to Licensee [***] Application. The license granted by
Licensee to Licensor under the Product Patent(s) pursuant to Section 3.5 of the C5 PLA shall, in relation to the Licensee [***] Application only, be amended by inserting a new Section 3.5A immediately after Section 3.5 as follows:

 “3.5A Licensee hereby grants to Licensor: 
  

	 	a)	 An exclusive, royalty-free, perpetual, irrevocable license (including the right to grant sub-licenses) in [***] under the Licensee [***] Application, for all uses and applications (including but not limited to the use of Affibody® Ligands),
outside the Field; and 

  
 2 

	 	b)	 A non-exclusive royalty-free, perpetual, irrevocable license (including
the right to grant sub-licenses) in [***] under any Know-how relating to the Licensee [***] Application, which is directly related to the use of any Affibody Ligand(s)
as such or the use of Affibody Molecule® Technology, to the extent necessary for Licensor to practice the Licensee [***] Application outside the Field in accordance with Section 3.5Aa)
above (as amended by this Amendment No. 2). For clarity, this non-exclusive license is only intended to allow Licensor and its sub-licenses freedom to operate under
the Licensee [***] Application as set out in Section 3.5Aa) (as amended herein) and not for any other purpose. Licensee will further not be required to perform any technological transfer or
“show-how” or similar activities as a consequence of this license.” 

  

	2.3	 Updated list of Licensed Patents. Appendix B of the C5 PLA contains a list of patents and patent
applications claiming the Affibody® Molecule Technology, which constitute Licensed Patents. Such Appendix B is hereby updated to add the Affibody Applications, as set out in Appendix 1
herein. 

  

	2.4	 Co-operation on Affibody Applications and Licensee Applications.
Each Party agrees to notify the other Party of any objection to or rejection of an Affibody Application or a Licensee Application by a patent authority that relates to the co- existence of an Affibody
Application and a Licensee Application (such as, for example, any double-patenting rejections or any rejection otherwise relating to an overlap in the scope of an Affibody Application and a Licensee Application), and to cooperate in good faith with
the other Party on the response to any such objection or rejection with the intention that, to the greatest extent reasonably possible, the response to any such objection or rejection is agreeable to both Parties, provided, that if the
Parties are unable to agree following good faith discussions for a reasonable period of time, each Party shall be free to submit its response as it deems required. In the event that either Party notifies the other Party that it wishes to further
amend the C5 PLA to address any such objection to or rejection of an Affibody Application or a Licensee Application, or the response thereto, in any country, and/or to include any additional licenses necessitated thereby, the Parties agree to
discuss and negotiate in good faith any such further amendments to the C5 PLA. All such good faith cooperation and discussions will aim to achieve an outcome that as closely as possible reflects having the Affibody Application(s) and Licensee
Application(s) being granted as coexisting patents and to reflect the license grants under the C5 PLA, and will otherwise be based on the principles set out in this Amendment No 2. 

 

	2.5	 Reestablishment of Information Sharing Committee. The Parties have agreed to re-establish the ISC. What is stated in Sections 6.2 and 6.2 a) of the C5 PLA shall apply except that Section 6.2 b) of the C5 PLA shall be amended as follows: 

“The ISC shall meet (either in person or by telephone conference) at least once every six (6) months until the First Commercial
Sale.” 

  
 3 

	3.	 OTHER 

  

	3.1	 Except as modified hereby, the C5 PLA shall remain in full force and effect between the Parties. Capitalized
terms used in this Amendment No 2 shall have the same meaning as set out in the C5 PLA unless explicitly stated otherwise. 

  

	3.2	 If there is a conflict between the terms of the C5 PLA and this Amendment No 2, this Amendment No 2 shall
prevail. 

  

	3.3	 For clarity, the provisions on confidentiality (section 13), indemnity, etc. (section 16), and choice of law
and arbitration (section 21) in the C5 PLA shall apply also to this Amendment No 2. 

  

 
 Signatures
follow 

  
 4 

					
	AFFIBODY AB	 		 	IPC RESEARCH, LLC
			
	/s/ David Bejker	 		 	/s/ Stephen Uden
	David Bejker, CEO	 		 	Stephen Uden,

  
 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00330-of-00352.parquet"}]]